EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Dupilumab efficacy and safety in patients with allergic bronchopulmonary aspergillosis

Arnaud Bourdin, Jonathan Corren, Anand Shah, Caroline G Baxter, Lavinia Davidescu, Heather Paleczny, Joseph A Chiarappa, Andrew P Fontenot, Paula Dakin, Elizabeth Laws, Jennifer Maloney, Lacey B Robinson und 2 weitere

Journal of Allergy and Clinical Immunology · 2026-11 · 158 (5) · 1380-1389

DOI: 10.1016/j.jaci.2026.08.021 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Allergy and Clinical Immunology, 2026-11. Verfasst von Arnaud Bourdin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Diseases, PhyMedExp, University of Montpellier, INSERM CNRS, Montpellier, France. Electronic address: a-bourdin@chu-montpel…. Hauptthemen laut MEDLINE: Aspergillosis, Allergic Bronchopulmonary, Antibodies, Monoclonal, Humanized, Asthma. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi US, Regeneron Pharmaceuticals Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Allergic bronchopulmonary aspergillosis (ABPA) is a complex allergic hypersensitivity reaction to Aspergillus species that can complicate and worsen concomitant asthma and is associated with an intense type 2 immune response in lower airways; there are no approved targeted therapies. OBJECTIVE: We sought to investigate dupilumab, a fully human mAb blocking IL-4 and IL-13 via the shared IL-4 receptor alpha, in patients with asthma and ABPA. METHODS: In this double-blind phase 2 trial, patients with asthma aged 12 years or older who met the clinical criteria for ABPA were randomized to dupilumab (n = 35) or placebo (n = 27) for 24 to 52 weeks; of these patients, 37.1% were receiving chronic systemic corticosteroids (SCSs). The primary end point was change from baseline in prebronchodilator FEV1 at 24 weeks. Additional end points included severe respiratory exacerbations and SCS use. RESULTS: At week 24, prebronchodilator FEV1 was significantly improved with dupilumab versus placebo (least squares mean change, 0.203 L vs 0.002 L; least squares mean treatment difference, 0.201 L; 95% CI, 0.08-0.33; P = .002). The adjusted annualized severe respiratory exacerbation rate per person-year was 0.695 (95% CI, 0.35-1.36) with dupilumab and 1.551 (95% CI, 0.75-3.22) with placebo, a 55.2% reduction (nominal P = .0627). At week 24, 71.4% of dupilumab recipients who required SCSs at baseline no longer required SCSs, compared with 14.3% receiving placebo. Overall safety was consistent with the known dupilumab safety profile. CONCLUSIONS: In patients with asthma and ABPA, dupilumab significantly improved lung function compared with placebo, reduced severe respiratory exacerbations, and was well tolerated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aspergillosis, Allergic BronchopulmonaryAntibodies, Monoclonal, HumanizedAsthmaHumansFemaleMaleAdultDouble-Blind MethodMiddle AgedChildTreatment OutcomeAdolescentAged

Stichwörter der Autor:innen

Allergic bronchopulmonary aspergillosisAspergillus fumigatusasthmadupilumabtype 2 inflammation

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Respiratory Diseases, PhyMedExp, University of Montpellier, INSERM CNRS, Montpellier, France. Electronic address: a-bourdin@chu-montpellier.fr.
  • David Geffen School of Medicine at UCLA, Los Angeles, Calif.
  • Respiratory Medicine, Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Department of Infectious Disease, School of Medicine, Centre of Bacterial Resistance Biology, Imperial Co…
  • Manchester University NHS Foundation Trust, Manchester, United Kingdom.
  • Department of Pneumology, University of Oradea, Oradea, Romania.
  • Regeneron Pharmaceuticals Inc, Tarrytown, NY.

Förderung

  • Sanofi US
  • Regeneron Pharmaceuticals Inc

Zitieren

APA

Bourdin, A., Corren, J., Shah, A., Baxter, C. G., Davidescu, L., Paleczny, H., Chiarappa, J. A., Fontenot, A. P., Dakin, P., Laws, E., Maloney, J., Robinson, L. B., Yancopoulos, G. D., & Radin, A. (2026). Dupilumab efficacy and safety in patients with allergic bronchopulmonary aspergillosis. Journal of Allergy and Clinical Immunology, 158(5), 1380-1389. https://doi.org/10.1016/j.jaci.2026.08.021

Vancouver

Bourdin A, Corren J, Shah A, Baxter CG, Davidescu L, Paleczny H, et al. Dupilumab efficacy and safety in patients with allergic bronchopulmonary aspergillosis. Journal of Allergy and Clinical Immunology. 2026;158(5):1380-1389. doi:10.1016/j.jaci.2026.08.021

BibTeX
@article{Bourdin2026,
  author = {Bourdin, Arnaud and Corren, Jonathan and Shah, Anand and Baxter, Caroline G and Davidescu, Lavinia and Paleczny, Heather and Chiarappa, Joseph A and Fontenot, Andrew P and Dakin, Paula and Laws, Elizabeth and Maloney, Jennifer and Robinson, Lacey B and Yancopoulos, George D and Radin, Allen},
  title = {Dupilumab efficacy and safety in patients with allergic bronchopulmonary aspergillosis},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2026},
  volume = {158},
  number = {5},
  pages = {1380--1389},
  doi = {10.1016/j.jaci.2026.08.021}
}
Kostenlos starten →